S100P interacts with integrin a7 and increases cancer cell migration and invasion in lung cancer

Supplementary Material




Figure 1. Inhibition of S100P reduced cell migration. Knockdown of S100P (**A**) decreased cell migration, but (**B**) did not affect cell proliferation in CL1-5 and A549 cells, as assessed by wound-healing assay or by WST-1 for indicated times. Data were as the mean±SD. *p<0.05 or significant difference between control and test groups; ns, non-significant




Figure 2. Overexpression of S100P increased cell migration. Elevated S100P (**A**) enhanced cell migration, but (**B**) did not affect cell proliferation in CL1-0 and A549 cells, as assessed by wound healing assay or by WST-1 for indicated times. Data were provided as the mean±SD. *p<0.05 or significant difference between control and test groups; ns, non-significant





Figure 3. The expression of ZEB1. S100P overexpressing CL1-0 cells were transfected with either control or ZEB1 siRNA. The mRNA level of ZEB1 was determined by qRT-PCR 24 h after transfection. Data were as the mean \pm SD. *p<0.05, or a significant difference between the two test groups






Figure 4. The role of FAK on cell migration and activation of Src and AKT. S100P overexpressing CL1-0 cells were treated with FAK inhibitors (20 μ M) and cell migration was assessed by the transwell system. The levels of various protein were assessed by immunoblot. Data were as mean \pm SD. *p<0.05, or a significant difference between the two test groups.




Figure 5. RAGE inhibition did not affect the S100P induced cell migration. S100P overexpressing CL1-0 cells were treated with RAGE inhibitors and cell migration was assessed by the transwell system. Data were as mean \pm SD. *p<0.05, or a significant difference between the two test groups.

Table 1. The mRNA transcript of S100P in non-tumor and tumor region in a cDNA array of lung cancer patients

	_	S100P							
	_ _			Low expression in tumor region			No difference in tumor region		
_	N	n tumor	%	n tumo	or reg	,	n	OF I	<u>egion</u> %
Tumor	24	13	54.2%	,	7 29	0.2%	1	4	16.6%
Gender	24								
Male	16	10	62.5%	4	1 25	5.0%)	2	12.5%
Female	8	3	37.5%	3	3 3 7	7.5%	1	2	25.0%